Acurx Pharmaceuticals Inc Ordinary Shares Logo
US00510M2035
A41DXH

Acurx Pharmaceuticals Inc Ordinary Shares

Loading quotes...

Forecast

Buy
  3
Hold
  0
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last quarter, Acurx Pharmaceuticals Inc Ordinary Shares had revenue of €0 and net profit of -€2.28M
(EUR) September 2026
YoY
Revenue 0 -
Gross profit 0 -
Net profit -2.28M 34.32%
EBITDA -2.28M 34.32%

Fundamentals

Metric Value
Market capitalization
€4.85M
Number of shares
5.56M
52-week high/low
€6.86 - €0.84
Dividends No
Beta
-2.05
P/E ratio
-0.34
PEG ratio
0.00
P/B ratio
0.00
P/S ratio
0.00

Company profile

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Name
Acurx Pharmaceuticals Inc Ordinary Shares
CEO
David Luci
Website
IPO
06/25/2021
Employees 4
đŸȘ

Parqet  uses cookies. Learn more